January 2025

Copyright Office AI Report Says Creative Prompting Doesn’t Constitute Authorship

“[G]iven current generally available technology, prompts alone do not provide sufficient human control to make users of an AI system the authors of the output.” – Copyright Office report The U.S. Copyright Office has released Part 2 of its multi-part artificial intelligence (AI) report, this one focusing on copyrightability of works made by or using […]

Copyright Office AI Report Says Creative Prompting Doesn’t Constitute Authorship Read More »

Last week’s conferences in Asia

Last week I gave two presentations in Asia.  On Monday, I presented The Law and Economics of Wrongful Patent Assertion at IEEM (Instituto de Estudos Europeus de Macau)’s 20th Intellectual Property Seminar, “Proportionality in Intellectual Property Law,” in Macau, S.A.R.  The presentation summarized some of my current book project, Wrongful Patent Assertion:  A Comparative Law

Last week’s conferences in Asia Read More »

A cold plunge into energy transition patent pools | Baker Botts L.L.P.

It’s not swimming pool weather yet, but here’s another one – companies looking to license and monetize patent portfolios relating to energy transition technologies are starting to pop up more often, and their scope of targets is wide. Companies looking to invest in these technologies should have these licensors on their radar and, even if

A cold plunge into energy transition patent pools | Baker Botts L.L.P. Read More »

Last week’s conferences in Asia

Last week I gave two presentations in Asia.  On Monday, I presented The Law and Economics of Wrongful Patent Assertion at IEEM (Instituto de Estudos Europeus de Macau)’s 20th Intellectual Property Seminar, “Proportionality in Intellectual Property Law,” in Macau, S.A.R.  The presentation summarized some of my current book project, Wrongful Patent Assertion:  A Comparative Law

Last week’s conferences in Asia Read More »

Thatchers v. Aldi: A Bitter Battle over Cider Branding | Morrison & Foerster LLP

On 20 January 2025, the Court of Appeal handed down its judgment in the trade mark dispute between Thatchers Cider Company Limited (“Thatchers”), the largest family-run independent cider producer in the UK, and Aldi Stores Limited (“Aldi”), the UK subsidiary of a German supermarket operator, in relation to Aldi’s alleged copycat cider product. The case

Thatchers v. Aldi: A Bitter Battle over Cider Branding | Morrison & Foerster LLP Read More »

Last week’s conferences in Asia

Last week I gave two presentations in Asia.  On Monday, I presented The Law and Economics of Wrongful Patent Assertion at IEEM (Instituto de Estudos Europeus de Macau)’s 20th Intellectual Property Seminar, “Proportionality in Intellectual Property Law,” in Macau, S.A.R.  The presentation summarized some of my current book project, Wrongful Patent Assertion:  A Comparative Law

Last week’s conferences in Asia Read More »

AI Legal Watch – January 2025 | Baker Botts L.L.P.

AI Governance in Focus for Proxy Season Glass Lewis, one of the leading proxy advisory firms, recently updated its policy guidelines for 2025 to include recommendations regarding board oversight of AI. In the new guidelines, Glass Lewis emphasizes the importance of effective oversight and disclosure of AI practices for companies engaging with AI but falls

AI Legal Watch – January 2025 | Baker Botts L.L.P. Read More »

Last week’s conferences in Asia

Last week I gave two presentations in Asia.  On Monday, I presented The Law and Economics of Wrongful Patent Assertion at IEEM (Instituto de Estudos Europeus de Macau)’s 20th Intellectual Property Seminar, “Proportionality in Intellectual Property Law,” in Macau, S.A.R.  The presentation summarized some of my current book project, Wrongful Patent Assertion:  A Comparative Law

Last week’s conferences in Asia Read More »

Amgen and Celltrion Settle Denosumab BPCIA Case | Goodwin

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding Celltrion’s denosumab biosimilar, CT-P41.  Pursuant to the agreement, Celltrion will be enjoined from making, using, selling, or importing CT-P41 into the

Amgen and Celltrion Settle Denosumab BPCIA Case | Goodwin Read More »

Last week’s conferences in Asia

Last week I gave two presentations in Asia.  On Monday, I presented The Law and Economics of Wrongful Patent Assertion at IEEM (Instituto de Estudos Europeus de Macau)’s 20th Intellectual Property Seminar, “Proportionality in Intellectual Property Law,” in Macau, S.A.R.  The presentation summarized some of my current book project, Wrongful Patent Assertion:  A Comparative Law

Last week’s conferences in Asia Read More »